The diseases currently indicated for SGLT2 inhibitor use, such as T2DM, heart failure, and chronic kidney disease, have been linked to mitochondrial dysfunction (125–127), so improving mitochondrial function may be an essential pathway for the beneficial effects seen in patients on SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and heart failure.